STOCK TITAN

Merus to Participate in William Blair's Biotech Focus Conference 2021

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
conferences

Rhea-AI Summary

On July 7, 2021, Merus N.V. (Nasdaq: MRUS) announced that CEO Bill Lundberg, M.D. will participate in the panel discussion titled Moving Beyond Monoclonals: The Potential of Multispecific Therapies at William Blair's Biotech Focus Conference 2021. The event is scheduled for July 14 at 11:20 a.m. ET. Investors can access the live webcast on the Company's website, with an archived presentation available for a limited time.

Merus specializes in developing innovative multispecific antibodies, known as Biclonics® and Triclonics®.

Loading...
Loading translation...
Argus Session date unavailable
-3.63% session move Open Argus
Details

News Market Reaction – MRUS

The recorded move for MRUS in the trading session of this news was -3.63%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., Chief Executive Officer of Merus, will participate in a panel discussion, Moving Beyond Monoclonals: The Potential of Multispecific Therapies, at William Blair's Biotech Focus Conference 2021 on Wednesday, July 14 at 11:20 a.m. ET.

The live webcast of the panel discussion will be available on the Investors page of the Company's website. An archived presentation will be available on the Merus website for a limited time.

About Merus
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website and twitter.


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the date and time of Merus N.V.'s CEO participation at the Biotech Focus Conference 2021?

Merus N.V.'s CEO, Bill Lundberg, will participate in the Biotech Focus Conference on July 14, 2021, at 11:20 a.m. ET.

Where can I watch the panel discussion featuring Merus N.V.'s CEO?

The panel discussion can be viewed live on the Investors page of Merus N.V.'s website.

What is the focus of the panel discussion at the William Blair's conference?

The panel discussion is titled Moving Beyond Monoclonals: The Potential of Multispecific Therapies.

What innovative therapies does Merus N.V. develop?

Merus N.V. develops innovative multispecific antibodies referred to as Biclonics® and Triclonics®.

What platform will host the archived presentation from the Merus N.V. panel?

An archived version of the presentation will be available on the Merus website for a limited time.

Keep reading